This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.
Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)
Norway
Algeta is a company focused on developing novel targeted therapies for patients with cancer based on its alpha-pharmaceutical platform. Company develops targeted therapies for patients with cancer based on its alpha-pharmaceutical platform.
AlgiPharma AS is a biopharmaceutical company with primary focus on respiratory diseases, wound healing and other conditions caused by microbial infections and biofilms.
The company?s vision is to be a leading biopharmaceutical company that develops disruptive alginate oligomer technologies in order to fight diseases effectively through innovative therapies.
The company?s vision is to be a leading biopharmaceutical company that develops disruptive alginate oligomer technologies in order to fight diseases effectively through innovative therapies.
APIM Therapeutics is a biotech company committed to the development of DNA repair- and cell cycle control-targeting anti-cancer agents. Company's pipeline of compounds includes a series of peptide drugs that target PCNA (Proliferating Cell Nuclear Antigen) and cell stress responses via APIM, a novel PCNA-interacting Stress Switch Peptide Motif identified in human AlkB homolog 2 (AlkB homolog 2 PCNA Interacting Motif).
Aqualis ASA is a clinical-stage oncology focused pharmaceutical company with a portfolio of novel anti-cancer drugs in development. These patented New Chemical Entities (NCEs) are novel, improved versions of well-established and commercially successful drugs, made using Aqualis ASA's Lipid Vector Technology (LVT), and may offer better efficacy and reduced side effects. Companion diagnostics designed to identify patient populations that may benefit from treatment with these candidates are being developed in parallel.
Avexxin AS is a clinical stage biopharmaceutical company focused on developing and commercializing novel small molecule therapeutics for patients with chronic inflammatory conditions. Avexxin's advanced understanding of the biology of the inflammatory process has resulted in a novel therapeutic approach for the treatment of psoriasis and other inflammatory disorders.
AVX 001 is being developed for the topical treatment of psoriasis (and other dermatological inflammatory disorders). The small molecule targets the group IVA phospholipase A2 (cPLA2) enzyme regulating the cytokine-induced activation of the proinflammatory nuclear transcription factor-kappa B (NF-kappa B). AVX 001 is a clinical stage asset undergoing an ascending-dose phase I/IIA trial in patients; top line results are expected in third quarter 2013.
AVX 002 and AVX235 are pre-clinical stage assets that also target cPLA2. They are being developed for the treatment of rheumatoid arthritis and glomerulonephritis,respectively. In preliminary animal testing, AVX235 exhibited significant anti-cancer activity. AVX001, AVX002 and AVX235 are lead compounds from two distinct chemical families being developed by Avexxin.
AVX 001 is being developed for the topical treatment of psoriasis (and other dermatological inflammatory disorders). The small molecule targets the group IVA phospholipase A2 (cPLA2) enzyme regulating the cytokine-induced activation of the proinflammatory nuclear transcription factor-kappa B (NF-kappa B). AVX 001 is a clinical stage asset undergoing an ascending-dose phase I/IIA trial in patients; top line results are expected in third quarter 2013.
AVX 002 and AVX235 are pre-clinical stage assets that also target cPLA2. They are being developed for the treatment of rheumatoid arthritis and glomerulonephritis,respectively. In preliminary animal testing, AVX235 exhibited significant anti-cancer activity. AVX001, AVX002 and AVX235 are lead compounds from two distinct chemical families being developed by Avexxin.
BerGenBio AS is a clinical stage biotech focused on cancer biology, the tumor micro environment, mechanisms of EMT and drug resistance. Built on a powerful discovery platform, CellSelect, BerGenBio identifies and validates novel drug targets, biomarkers and develops first in class drugs against these targets. The company's lead drug, BGB324, is the first highly selective Axl kinase inhibitor in clinical development. It recently completed a phase Ia clinical trial to access safety, pharmacokinetics and tolerability.
Biolink Group is a life science drug discovery company, doing R&D on small molecules based on own synthesized small anthocyanin molecules, their metabolites and other anthocyanin related small synthesized molecules.
Bionor Pharma ASA is an innovative development company within the field of peptide.based vaccines. The company also manages a portfolio of nutritional and weight management supplements.
Biosergen AS is a biotech company developing new drugs based on biosynthetic engineering of natural products, combined with chemical synthesis. Biosergen is currently running one development program, for systemic fungal infections where a candidate drug has been selected, BSG005G.
C10 PHARMA is a Norwegian company developing a new generation ketolide as a potential monotheraphy in the treatment of severe and moderate CABP and other respiratory tract infections in both hospitalized and community patients:
* Oral and IV formulation to allow early hospital patients discharge by IV-to-PO switch
* Well-balanced distribution in blood and tissues for prevention and/or treatment also of systemic infections
* No/limited drug-drug interaction to facilitate antibiotic treatment in the presence of multiple co-morbidities, especially in elderly patients
* Further improved class safety (QT, hepatotoxicity)
* Broad coverage of CABP pathogens including macrolide- and penicillin-resistant strains
* Low propensity for resistance development
The development program is built on a proprietary chemistry platform based on modifications of the carbon-10 position enabling novel modifications of the ketolide scaffold.
The company entered lead optimization phase early 2012, with the aim of selecting a preclinical candidate during 2012. The company is planning to raise funding sometime during 2H:2012 to take the company through phase 1.
Their current investors are Novo Seed (Denmark) and Sarsia Seed (Norway).
* Oral and IV formulation to allow early hospital patients discharge by IV-to-PO switch
* Well-balanced distribution in blood and tissues for prevention and/or treatment also of systemic infections
* No/limited drug-drug interaction to facilitate antibiotic treatment in the presence of multiple co-morbidities, especially in elderly patients
* Further improved class safety (QT, hepatotoxicity)
* Broad coverage of CABP pathogens including macrolide- and penicillin-resistant strains
* Low propensity for resistance development
The development program is built on a proprietary chemistry platform based on modifications of the carbon-10 position enabling novel modifications of the ketolide scaffold.
The company entered lead optimization phase early 2012, with the aim of selecting a preclinical candidate during 2012. The company is planning to raise funding sometime during 2H:2012 to take the company through phase 1.
Their current investors are Novo Seed (Denmark) and Sarsia Seed (Norway).
Epitarget AS is a privately owned Scandinavian life science company dedicated to improving cancer treatment by nanotechnology drug delivery. It develops a technology for local release of cytostatic drugs by means of ultrasound. The company focuses on developing technology to deliver approved and established cancer drugs exactly where they are needed by means of ultrasound mediated drug release.
Nordic Nanovector AS is a privately held company based in Oslo, Norway. The company's mission is to develop innovative radioimmunotherapeutics that target difficult to treat cancers using the company?s proprietary nanovector targeting technology.